Xeris Biopharma Holdings
XERS
101 hedge funds and large institutions have $89.3M invested in Xeris Biopharma Holdings in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 11 closing their positions.
1,408% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $148K
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less capital invested
Capital invested by funds: $91.3M → $89.3M (-$1.98M)
1.64% less ownership
Funds ownership: 43.75% → 42.11% (-1.6%)
2% less funds holding
Funds holding: 103 → 101 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.12M |
| 2 |
BlackRock
New York
|
+$367K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$358K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$297K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.49M |
| 2 |
Millennium Management
New York
|
-$851K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$303K |
| 4 |
Jane Street
New York
|
-$246K |
| 5 |
Lazard Asset Management
New York
|
-$193K |
XERS Hedge Fund Activity: Q3 2022 in Review
101 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q3 2022, worth a combined $89.3M — down 2.2% from $91.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of XERS and 9 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 29 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.12M. The largest seller was Armistice Capital, cutting an estimated $5.49M.
- 101 institutional investors held Xeris Biopharma Holdings (XERS) as of Q3 2022, down from 103 in Q2 2022.
- Funds reported $89.3M of Xeris Biopharma Holdings stock for Q3 2022, down 2.2% quarter-over-quarter.
- 9 funds opened new Xeris Biopharma Holdings positions in Q3 2022 and 11 closed out, a net change of -2 holders.
- The largest Xeris Biopharma Holdings buyer in Q3 2022 was Stonepine Capital Management, an estimated $2.12M added.
- The largest Xeris Biopharma Holdings seller in Q3 2022 was Armistice Capital, an estimated $5.49M sold.
Based on aggregated 13F filings for Q3 2022.